Berger W. – TechConnect Briefs

Enhancement of anticancer action of traditional (doxorubicin and cisplatin) and experimental (landomycin A) drugs by their delivery in vivo with novel C60-fullerene-based nanocarriers possessing innate ROS-modulating activity

Panchuk R., Prylutska S., Skorokhyd N., Lehka L., Skivka L., Hurmach V., Evstigneev M., Piosik J., Berger W., Prylutskyy Yu., Scharff P., Stoika R., Vari S., Institute of Cell Biology NAS of Ukraine, UA

Rapid development of multi-drug resistance of tumor cells to chemotherapy caused by the over-expression of specific ABC-transporter proteins and/or multiple defects in genes involved in cell cycle and apoptosis regulation in cancer cells frequently leads [...]

Conjugation of anticancer drugs with novel PEG-containing nanocarrier provides circumvention of drug-resistance mechanisms in vitro and protects of general toxicity in vivo

Kоbylinska L., Panchuk R., Skorohyd N., Senkiv Y., Heffeter P., Berger W., Boiko N., Mitina N., Zaichenko A., Lesyk R., Zіmenkovsky B., Stoika R., Vari G.S., Danylo Halytsky Lviv National Medical University, UA

In the last decade, the development of targeted drug delivery with conjugated nanoparticles brings more drug molecules to the diseased sites, at the same time reducing a systemic drug exposure. Polyethylene glycol (PEG) conjugation is [...]